Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor ...
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically ...
March 17, 2009 (Hollywood, Florida) — The management of dermatologic toxicities associated with the use of epidermal growth-factor-receptor (EGFR) inhibitors in cancer patients is in a nascent stage ...
Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer. If you have the appropriate software installed, you can download article ...
TYK Medicines Inc. made a strong debut on the main board of the Hong Kong Stock Exchange (HKSE), raising HK$579 million (US$74.32 million) to commercialize its lead compound, EGFR inhibitor TY-9591, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback